Comparative Pharmacology
Head-to-head clinical analysis: ETODOLAC versus TOLECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETODOLAC versus TOLECTIN.
ETODOLAC vs TOLECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Extended-release: 400-1000 mg orally once daily.
400-600 mg orally three times daily; maximum 1.8 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6.5-7.5 hours (range 5-8 hours). With multiple dosing, the half-life remains unchanged, indicating linear kinetics. No accumulation in normal renal function.
Clinical Note
moderateEtodolac + Gatifloxacin
"Etodolac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateEtodolac + Rosoxacin
"Etodolac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateEtodolac + Levofloxacin
"Etodolac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateEtodolac + Trovafloxacin
"Etodolac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Renal excretion (72% as metabolites, including glucuronides and hydroxylated derivatives, less than 1% unchanged); fecal excretion (16%, primarily as metabolites); biliary excretion contributes to enterohepatic recirculation.
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Category D/X
Category C
NSAID
NSAID